Embecta Corp. (EMBC) Tops Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall St futures gain as pause in US-Iran hostilities lifts sentiment
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices hit one-week low after US, Iran pause fighting over weekend
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Taiwan Semi (TSM) PT Raised to $530 at Needham
- Oil prices hit one-week low after US, Iran pause fighting over weekend
Embecta Corp. Reports Third Quarter Fiscal 2022 Financial Results
August 15, 2022 6:30 AM EDTPARSIPPANY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company (BD), today reported financial results for the three and nine month periods ended June 30, 2022.
Our fiscal third quarter 2022 results reinforce our core strength and further position embecta towards creating a company that allows for a life unlimited by diabetes, said Devdatt Dev Kurdikar, Chief Executive Officer of embecta. Despite a challenging macro-economic environment, we delivered resilient commercial performance... More
